Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of Vedolizumab in Biologic-naïve Korean Patients with Moderate to Severe Inflammatory Bowel Disease
KCT0006087Phase 3Withdrawn
- Sponsor
- Takeda
- Start
- Mar 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of vedolizumab in Crohn's disease, autoimmune colitis, sponsored by Takeda. Planned start Mar 2022; status: withdrawn.
02
Drugs
vedolizumab
03
Conditions
Crohn's diseaseautoimmune colitis
Beyond the preview
Go deeper on KCT0006087.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0006087.